Skip to search formSkip to main contentSkip to account menu

NBI-98854

National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

valbenazine

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Schizophrenia or Schizoaffective Disorder.
BACKGROUND Valbenazine (VBZ, NBI-98854) is a novel vesicular monoamine transporter 2 (VMAT2) inhibitor approved for the treatment… 
2017
2017
Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Mood Disorder.
BACKGROUND Valbenazine (VBZ, NBI-98854) is a novel vesicular monoamine transporter 2 (VMAT2) inhibitor approved for the treatment… 
2017
2017
Long-Term Safety and Tolerability of Valbenazine (NBI-98854) in Subjects with Tardive Dyskinesia and a Diagnosis of Schizophrenia or Mood Disorder.
BACKGROUND The short-term safety profile of once-daily valbenazine (NBI-98854) has been evaluated in several double-blind… 
2017
2017
Pharmacologic Characteristics of Valbenazine (NBI-98854) and its Metabolites (P2.025)
Objective: To characterize the pharmacology of valbenazine and its metabolites in vitro . Background: Valbenazine (NBI-98854), a… 
2017
2017
Safety and Tolerability of Valbenazine (NBI-98854) in Subjects with Tardive Dyskinesia: Results of Long-Term Exposure Data from Three Studies (P2.017)
Objective: To assess the long-term safety and tolerability of valbenazine (NBI-98854) for the treatment of tardive dyskinesia (TD… 
2017
2017
Efficacy of Valbenazine (NBI-98854) in Subjects with Tardive Dyskinesia: Results of a Long-Term Study (KINECT 3 Extension) (S56.005)
Objective: To assess the long-term efficacy of valbenazine (NBI-98854) in treating tardive dyskinesia (TD). Background… 
2016
2016
Open-Label Extension of KINECT: A Phase 2 Study of Valbenazine (NBI-98854) for Tardive Dyskinesia (S27.001)
Objective: To assess safety, tolerability and persistence of effect of valbenazine in subjects with schizophrenia or… 
2016
2016
A Phase 2 Study of Valbenazine (NBI-98854) for Treatment of Tardive Dyskinesia: KINECT 2 (S27.007)
Objective: To assess efficacy, safety and tolerability of valbenazine for Tardive Dyskinesia (TD). Background: Valbenazine is… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)